Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study-Reference-Cited by-同舟云学术

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study

Published:2019-01 Issue:1 Volume:139 Page:115-123
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Wilkinson Nina,Tsakok Teresa^ORCID,Dand Nick,Bloem Karien,Duckworth Michael,Baudry David,Pushpa-Rajah Angela,Griffiths Christopher E.M.,Reynolds Nick J.,Barker Jonathan,Warren Richard B.,Burden A. David,Rispens Theo,Stocken Deborah,Smith Catherine

Funder

PSORT

Medical Research Council

MRC Clinical Research Training Fellowship

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference22 articles.

1. Steady-state pharmacokinetics (PK) of adalimumab (HUMIRA (TM), Abbott) following 40 mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy;Awni;Arthritis Rheum,2003

2. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease;Baert;N Engl J Med,2003

3. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis;Baert;Aliment Pharmacol Ther,2014

4. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis;Chen;Ann Rheum Dis,2015

5. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis;Garces;Ann Rheum Dis,2013

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases;Pediatric Rheumatology;2024-01-02

2. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR);British Journal of Dermatology;2023-12-05

3. Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab;The Journal of Applied Laboratory Medicine;2023-09-02

4. Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis;Journal of Investigative Dermatology;2023-09

5. Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience;Journal of Investigative Dermatology;2023-09